For Immediate Release
Chicago, IL - May 14, 2012 - Zacks.com announces the list of
stocks featured in the Analyst Blog. Every day the Zacks Equity
Research analysts discuss the latest news and events impacting
stocks and the financial markets. Stocks recently featured in the
blog include
Covidien
(
COV
),
General Electrical
(
GE
),
Becton, Dickinson and Company
(
BDX
),
Johnson and Johnson
(
JNJ
) and
CR Bard Inc
. (
BCR
).
Get the most recent insight from Zacks Equity Research with the
free Profit from the Pros newsletter:
http://at.zacks.com/?id=5513
Here are highlights from Friday's Analyst Blog:
Covidien Teams Up with GE Health
Large-cap medical technology company,
Covidien
(
COV
) recently announced a five-year worldwide collaboration with GE
Healthcare, a division of
General Electrical
(
GE
). The collaboration will allow GE Healthcare, a market leader in
biomedical devices and services, to include the measurement
technology used by Covidien in its patient monitoring systems.
GE Healthcare asserts that the collaboration will improve the
standard of patient monitoring and safety. The alliance also
manifests an undertaking by GE Healthcare to maintain an extensive
patient monitoring system that is easily accessible to clinicians
and healthcare administrators.
Following this collaboration, GE's monitoring systems including
CARESAPE Monitor B850 and CARESCAPE Monitor B650 will have easy
access to the measurement technologies of Covidien, enhancing the
clinical information available to physicians.
On the other hand, the collaboration will enhance the technology
portfolio of Covidien associated with patient monitoring. The
Nellcor pulse oximetry with Oximac Technology, INVOS Cerebral/
Somatic Oximetry and BIS Brain Monitoring will get the maximum
advantage.
The oximetry and monitoring products are a part of Medical
Devices segment, the primary growth driver of Covidien. These
products edged up by 4% year over year in the second quarter,
reflecting double-digit growth in sale of monitors (Nellcor, INVOS,
BIS). The alliance will leverage the sales growth of monitors,
leading to an increase in market share of the oximetry and
monitoring sub segment, which was reportedly flat during the first
quarter.
GE Healthcare has industry experience of about 100 years in the
development and production of healthcare devices and services.
The company will be able to assimilate clinical measurements
and other patient health parameters at the point of care. It will
thereby support accurate decision making after the alliance.
Also, Covidien management believes that the specialized
measurement technology hitched with the patient monitors at GE
Healthcare will ensure greater precision in patient care and
safety.
Covidien is a leading developer, manufacturer and distributor of
medical devices and services on a global scale. Its business
segments overlap with the business of its competitors such as
Becton, Dickinson and Company
(
BDX
),
Johnson and Johnson
(
JNJ
) and
CR Bard Inc
. (
BCR
) among others.
With a growth rate higher than its competitors, the stock
currently retains a Zacks #2 Rank, which translates into a
short-term Buy. However, we maintain a long-term Neutral
recommendation on the stock.
Want more from Zacks Equity Research? Subscribe to the free
Profit from the Pros newsletter:
http://at.zacks.com/?id=5515
.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and
qualitative analysis to help investors know what stocks to buy and
which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives
them keen insights to developments that affect company profits and
stock performance. Recommendations and target prices are six-month
time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides
highlights of the latest analysis from Zacks Equity Research.
Subscribe to this free newsletter today:
http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc.,
which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew
he could find patterns in stock market data that would lead to
superior investment results. Amongst his many accomplishments was
the formation of his proprietary stock picking system; the Zacks
Rank, which continues to outperform the market by nearly a 3 to 1
margin. The best way to unlock the profitable stock recommendations
and market insights of Zacks Investment Research is through our
free daily email newsletter; Profit from the Pros. In short, it's
your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros
at
http://at.zacks.com/?id=5518
.
Visit
http://www.zacks.com/performance
for information about the performance numbers displayed in this
press release.
Follow us on Twitter:
http://twitter.com/zacksresearch
Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an
offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
BARD C R INC (BCR): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis
Report
COVIDIEN PLC (COV): Free Stock Analysis Report
GENL ELECTRIC (GE): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
Report
To read this article on Zacks.com click here.